[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511432":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":19,"locations":26,"responsibleParty":42,"collaborators":11,"id":44,"slug":45,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":46,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Poitiers University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patient with early onset Alzheimer's disease","EXPERIMENTAL",null,[13],"Other: MRI follow-up",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":11},"MRI follow-up","MRI follow-up for patient with early onset Alzheimer's disease",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Adrien JULIAN, Dr","CONTACT","05.49.44.44.44","+33","adrien.julian@chu-poitiers.fr",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":11,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Chu Poitiers","RECRUITING","Poitiers","France","FR",{"type":34,"coordinates":35},"Point",[36,37],0.34348,46.58261,{"lat":37,"lon":36},[40],{"name":41,"role":22,"phone":11,"phoneExt":11,"email":11},"Adrien Julian",{"type":43,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100511432","new-imaging-biomarkers-predictive-of-ma-progression-100511432",false,"NCT05939362","New Imaging Biomarkers Predictive of MA Progression","Identifying Imaging Biomarkers Predictive of Disability Progression in Alzheimer's Disease: Pilot Study","MR7T-PRADA","Inclusion Criteria:\n\n* French-speaking patients aged 60 to 90 years,\n* Patient in the context of Alzheimer's disease \\* for which imaging after MRI is prescribed as part of the usual diagnostic process,\n\n  \\*Alzheimer's disease is diagnosed by the doctor of the memory consultation and is defined by :Evidence of a storage disorder in verbal episodic memory at LR\u002FRI defined by a sum of LR \\\u003C 17\u002F48 and sum of RT \\\u003C 40\u002F48 +\u002F- Impairment of executive functions possible (BREF, TMT grefex, verbal fluencies) +\u002F- Impairment of instrumental functions possible (Grémots noun naming, Rey's figure, Mahieux's Battery).\n* MMSE score ≥18,\n* Written informed consent after the patient has been informed,\n* Progressive decline for at least 6 months.\n\nExclusion Criteria:\n\n--Partially or completely illiterate patient unable to read and write,\n\n* Patient with an absolute contraindication to 7T MRI\n* Severe psychiatric pathology not balanced,\n* Non-degenerative neurological disease (stroke, multiple sclerosis ...),\n* Patient with tumor or inflammatory pathology, or vascular leukopathy visualized in MRI (Fazekas score \\> 3)","ALL","60 Years","90 Years",{"count":56,"type":57},80,"ESTIMATED","INTERVENTIONAL",[60],"NA","The pathophysiology of AD is complex. In addition to amyloid plaques and neurofibrillary degeneration, there is a metabolic alteration of the energy pathways, oxidative phosphorylation and glycolysis, which are involved in brain function. Several authors have shown a series of early metabolic dysregulations via an increase in phosphorylation at the origin of neuronal death.\n\nUltra-high field imaging (7T MRI) may allow, with its better spatial resolution and advanced imaging techniques, to shed light on the mechanisms of progression of Alzheimer's disease. A Magnetic Resonance Spectroscopy (MRS) examination can be coupled to brain MRI without additional risk for the patient. Multinuclear 1H-31P metabolic imaging is a promising tool that can provide information on the metabolic evolutionary profile of AD. Thus, we propose a longitudinal study in patients with early-stage AD on 7T MRI-MRS.",[63,64,65,66,67],"Alzheimer Disease","Magnetic Resonance Spectroscopy","Ultra High Field 7T","Progression of Disease","MR Biomarkers","2024-12-05",{"date":70,"type":71},"2024-12-10","ACTUAL",{"date":73,"type":71},"2023-10-02",{"date":75,"type":57},"2028-01-15",{"name":5,"class":6},1]